Factors influencing appropriate use of interventions for management of women experiencing preterm birth: A mixed-methods systematic review and narrative synthesis.


Journal

PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360

Informations de publication

Date de publication:
08 2022
Historique:
received: 14 12 2021
accepted: 12 07 2022
entrez: 23 8 2022
pubmed: 24 8 2022
medline: 26 8 2022
Statut: epublish

Résumé

Preterm birth-related complications are the leading cause of death in newborns and children under 5. Health outcomes of preterm newborns can be improved with appropriate use of antenatal corticosteroids (ACSs) to promote fetal lung maturity, tocolytics to delay birth, magnesium sulphate for fetal neuroprotection, and antibiotics for preterm prelabour rupture of membranes. However, there are wide disparities in the rate and consistency in the use of these interventions across settings, which may underlie the differential health outcomes among preterm newborns. We aimed to assess factors (barriers and facilitators) affecting the appropriate use of ACS, tocolytics, magnesium sulphate, and antibiotics to improve preterm birth management. We conducted a mixed-methods systematic review including primary qualitative, quantitative, and mixed-methods studies. We searched MEDLINE, EMBASE, CINAHL, Global Health, and grey literature from inception to 16 May 2022. Eligible studies explored perspectives of women, partners, or community members who experienced preterm birth or were at risk of preterm birth and/or received any of the 4 interventions, health workers providing maternity and newborn care, and other stakeholders involved in maternal care (e.g., facility managers, policymakers). We used an iterative narrative synthesis approach to analysis, assessed methodological limitations using the Mixed Methods Appraisal Tool, and assessed confidence in each qualitative review finding using the GRADE-CERQual approach. Behaviour change models (Theoretical Domains Framework; Capability, Opportunity, and Motivation (COM-B)) were used to map barriers and facilitators affecting appropriate use of these interventions. We included 46 studies from 32 countries, describing factors affecting use of ACS (32/46 studies), tocolytics (13/46 studies), magnesium sulphate (9/46 studies), and antibiotics (5/46 studies). We identified a range of barriers influencing appropriate use of the 4 interventions globally, which include the following: inaccurate gestational age assessment, inconsistent guidelines, varied knowledge, perceived risks and benefits, perceived uncertainties and constraints in administration, confusion around prescribing and administering authority, and inadequate stock, human resources, and labour and newborn care. Women reported hesitancy in accepting interventions, as they typically learned about them during emergencies. Most included studies were from high-income countries (37/46 studies), which may affect the transferability of these findings to low- or middle-income settings. In this study, we identified critical factors affecting implementation of 4 interventions to improve preterm birth management globally. Policymakers and implementers can consider these barriers and facilitators when formulating policies and planning implementation or scale-up of these interventions. Study findings can inform clinical preterm birth guidelines and implementation to ensure that barriers are addressed, and enablers are reinforced to ensure these interventions are widely available and appropriately used globally.

Sections du résumé

BACKGROUND
Preterm birth-related complications are the leading cause of death in newborns and children under 5. Health outcomes of preterm newborns can be improved with appropriate use of antenatal corticosteroids (ACSs) to promote fetal lung maturity, tocolytics to delay birth, magnesium sulphate for fetal neuroprotection, and antibiotics for preterm prelabour rupture of membranes. However, there are wide disparities in the rate and consistency in the use of these interventions across settings, which may underlie the differential health outcomes among preterm newborns. We aimed to assess factors (barriers and facilitators) affecting the appropriate use of ACS, tocolytics, magnesium sulphate, and antibiotics to improve preterm birth management.
METHODS AND FINDINGS
We conducted a mixed-methods systematic review including primary qualitative, quantitative, and mixed-methods studies. We searched MEDLINE, EMBASE, CINAHL, Global Health, and grey literature from inception to 16 May 2022. Eligible studies explored perspectives of women, partners, or community members who experienced preterm birth or were at risk of preterm birth and/or received any of the 4 interventions, health workers providing maternity and newborn care, and other stakeholders involved in maternal care (e.g., facility managers, policymakers). We used an iterative narrative synthesis approach to analysis, assessed methodological limitations using the Mixed Methods Appraisal Tool, and assessed confidence in each qualitative review finding using the GRADE-CERQual approach. Behaviour change models (Theoretical Domains Framework; Capability, Opportunity, and Motivation (COM-B)) were used to map barriers and facilitators affecting appropriate use of these interventions. We included 46 studies from 32 countries, describing factors affecting use of ACS (32/46 studies), tocolytics (13/46 studies), magnesium sulphate (9/46 studies), and antibiotics (5/46 studies). We identified a range of barriers influencing appropriate use of the 4 interventions globally, which include the following: inaccurate gestational age assessment, inconsistent guidelines, varied knowledge, perceived risks and benefits, perceived uncertainties and constraints in administration, confusion around prescribing and administering authority, and inadequate stock, human resources, and labour and newborn care. Women reported hesitancy in accepting interventions, as they typically learned about them during emergencies. Most included studies were from high-income countries (37/46 studies), which may affect the transferability of these findings to low- or middle-income settings.
CONCLUSIONS
In this study, we identified critical factors affecting implementation of 4 interventions to improve preterm birth management globally. Policymakers and implementers can consider these barriers and facilitators when formulating policies and planning implementation or scale-up of these interventions. Study findings can inform clinical preterm birth guidelines and implementation to ensure that barriers are addressed, and enablers are reinforced to ensure these interventions are widely available and appropriately used globally.

Identifiants

pubmed: 35998205
doi: 10.1371/journal.pmed.1004074
pii: PMEDICINE-D-21-05120
pmc: PMC9398034
doi:

Substances chimiques

Anti-Bacterial Agents 0
Tocolytic Agents 0
Magnesium Sulfate 7487-88-9

Types de publication

Journal Article Systematic Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1004074

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Commentaires et corrections

Type : ErratumIn

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

BJOG. 2010 Oct;117(11):1344-9
pubmed: 20633002
BMJ Qual Saf. 2016 Mar;25(3):173-81
pubmed: 26056321
Am J Obstet Gynecol. 1987 Jul;157(1):11-2
pubmed: 3605242
Obstet Gynecol. 2001 Jan;97(1):140-6
pubmed: 11152923
Implement Sci. 2018 Jan 25;13(Suppl 1):14
pubmed: 29384077
N Engl J Med. 2020 Dec 24;383(26):2514-2525
pubmed: 33095526
Aust N Z J Obstet Gynaecol. 2004 Oct;44(5):400-3
pubmed: 15387859
Int J Womens Health. 2019 Jan 30;11:75-95
pubmed: 30774452
Implement Sci. 2018 Jan 25;13(Suppl 1):4
pubmed: 29384080
BMC Pregnancy Childbirth. 2015 Dec 22;15:347
pubmed: 26694323
BMC Med Res Methodol. 2012 Nov 27;12:181
pubmed: 23185978
Implement Sci. 2018 Jan 25;13(Suppl 1):9
pubmed: 29384078
J Fam Pract. 1997 Oct;45(4):336-40
pubmed: 9343055
Aust N Z J Obstet Gynaecol. 2020 Feb;60(1):44-48
pubmed: 31119725
Aust N Z J Obstet Gynaecol. 2013 Feb;53(1):86-9
pubmed: 23106226
BMC Pregnancy Childbirth. 2014 Apr 02;14:123
pubmed: 24690288
Cochrane Database Syst Rev. 2009 Jan 21;(1):CD004661
pubmed: 19160238
Implement Sci. 2018 Jan 25;13(Suppl 1):13
pubmed: 29384081
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Cochrane Database Syst Rev. 2014 Feb 05;(2):CD004352
pubmed: 24500892
BMJ. 2016 Oct 12;355:i5044
pubmed: 27733360
Int J Qual Health Care. 2016 Dec 01;28(6):682-688
pubmed: 27614015
Lancet Glob Health. 2019 Jan;7(1):e37-e46
pubmed: 30389451
Ginecol Obstet Mex. 2000 Jul;68:291-5
pubmed: 11006643
Glob Health Sci Pract. 2018 Dec 27;6(4):644-656
pubmed: 30573455
BJOG. 2020 Mar;127(4):467-476
pubmed: 31803995
Am J Obstet Gynecol. 2015 May;212(5):671.e1-7
pubmed: 25555660
BMC Pregnancy Childbirth. 2017 Sep 13;17(1):304
pubmed: 28903747
Pediatrics. 1972 Oct;50(4):515-25
pubmed: 4561295
Cochrane Database Syst Rev. 2013 Aug 29;(8):CD006764
pubmed: 23990333
Infect Dis Obstet Gynecol. 2005 Mar;13(1):5-10
pubmed: 16040321
J Med Assoc Thai. 2005 Mar;88(3):307-13
pubmed: 15962636
J Perinatol. 2015 May;35(5):338-43
pubmed: 25357097
Eur J Obstet Gynecol Reprod Biol. 2006 Sep-Oct;128(1-2):142-7
pubmed: 16574303
BMC Med Res Methodol. 2008 Jul 10;8:45
pubmed: 18616818
Am J Obstet Gynecol. 2015 Sep;213(3):398.e1-11
pubmed: 25957021
Trials. 2019 Aug 16;20(1):507
pubmed: 31420064
Implement Sci. 2018 Jan 25;13(Suppl 1):2
pubmed: 29384079
J Nurs Res. 2006 Mar;14(1):65-74
pubmed: 16547907
BMC Pregnancy Childbirth. 2015;15 Suppl 2:S3
pubmed: 26390927
Cochrane Database Syst Rev. 2014 Jun 05;(6):CD002255
pubmed: 24901312
Implement Sci. 2017 Jun 21;12(1):77
pubmed: 28637486
Midwifery. 2012 Dec;28(6):e857-64
pubmed: 22169524
BMC Pregnancy Childbirth. 2015 Aug 18;15:176
pubmed: 26283623
Int J Gynaecol Obstet. 2021 Oct;155(1):26-30
pubmed: 34520057
J Obstet Gynaecol Can. 2007 Feb;29(2):117-124
pubmed: 17346482
Implement Sci. 2018 Jan 25;13(Suppl 1):10
pubmed: 29384082
J Matern Fetal Neonatal Med. 2020 Sep;33(17):2941-2949
pubmed: 30678514
Am J Perinatol. 2019 Jan;36(2):200-204
pubmed: 30016819
J Perinatol. 2015 Mar;35(3):161-6
pubmed: 25254331
BMJ Open Qual. 2017 Oct 12;6(2):e000189
pubmed: 29450301
J Obstet Gynaecol Can. 2002 Apr;24(4):321-9
pubmed: 12196868
J Perinatol. 2015 May;35(5):344-8
pubmed: 25474555
Cochrane Database Syst Rev. 2013 Dec 05;(12):CD000246
pubmed: 24307518
Reprod Health. 2013 Jan 29;10:4
pubmed: 23360713
Implement Sci. 2011 Apr 23;6:42
pubmed: 21513547
BMC Pregnancy Childbirth. 2016 Sep 05;16:259
pubmed: 27596254
Ir J Med Sci. 2011 Mar;180(1):63-7
pubmed: 20953982
Aust N Z J Obstet Gynaecol. 2004 Feb;44(1):35-8
pubmed: 15089866
Aust N Z J Obstet Gynaecol. 1989 Feb;29(1):5-8
pubmed: 2751577
Glob Health Sci Pract. 2021 Sep 30;9(3):575-589
pubmed: 34593583
J Pediatr. 1996 Feb;128(2):167-72
pubmed: 8636806
Aust N Z J Obstet Gynaecol. 2017 Feb;57(1):25-32
pubmed: 27861707
Am J Obstet Gynecol. 1995 Jul;173(1):312-6
pubmed: 7631711
Cochrane Database Syst Rev. 2020 Dec 25;12:CD004454
pubmed: 33368142
Int J Qual Health Care. 2002 Jun;14(3):175-81
pubmed: 12108528
BMC Health Serv Res. 2016 Oct 28;16(1):617
pubmed: 27793150
Hu Li Za Zhi. 2006 Dec;53(6):45-52
pubmed: 17160869
Lancet Glob Health. 2015 Oct;3(10):e589-90
pubmed: 26310802

Auteurs

Rana Islamiah Zahroh (RI)

Gender and Women's Health, Centre for Health Equity, School of Population and Global Health, The University of Melbourne, Carlton, Australia.

Alya Hazfiarini (A)

Gender and Women's Health, Centre for Health Equity, School of Population and Global Health, The University of Melbourne, Carlton, Australia.

Katherine E Eddy (KE)

Maternal, Child and Adolescent Health Program, Burnet Institute, Melbourne, Australia.

Joshua P Vogel (JP)

Maternal, Child and Adolescent Health Program, Burnet Institute, Melbourne, Australia.

Ӧzge Tunçalp (Ӧ)

UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Sexual and Reproductive Health and Research World Health Organization, Geneva, Switzerland.

Nicole Minckas (N)

Department of Maternal, Newborn, Child and Adolescent Health, World Health Organization, Geneva, Switzerland.

Fernando Althabe (F)

UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Sexual and Reproductive Health and Research World Health Organization, Geneva, Switzerland.

Olufemi T Oladapo (OT)

UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Sexual and Reproductive Health and Research World Health Organization, Geneva, Switzerland.

Meghan A Bohren (MA)

Gender and Women's Health, Centre for Health Equity, School of Population and Global Health, The University of Melbourne, Carlton, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH